TARCEVA Drug Patent Profile

When do Tarceva patents expire, and when can generic versions of Tarceva launch?

Tarceva is a drug marketed by Osi Pharms and is included in one NDA.

The generic ingredient in TARCEVA is erlotinib hydrochloride. There are twenty-five drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the erlotinib hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tarceva

A generic version of TARCEVA was approved as erlotinib hydrochloride by RISING on June 11^th, 2014.

Summary for TARCEVA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TARCEVA

Paragraph IV (Patent) Challenges for TARCEVA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TARCEVA	Tablets	erlotinib hydrochloride	25 mg	021743	1	2008-11-18

US Patents and Regulatory Information for TARCEVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Osi Pharms	TARCEVA	erlotinib hydrochloride	TABLET;ORAL	021743-001	Nov 18, 2004		DISCN	Yes	No
Osi Pharms	TARCEVA	erlotinib hydrochloride	TABLET;ORAL	021743-002	Nov 18, 2004		DISCN	Yes	No
Osi Pharms	TARCEVA	erlotinib hydrochloride	TABLET;ORAL	021743-003	Nov 18, 2004		DISCN	Yes	No

International Patents for TARCEVA

See the table below for patents covering TARCEVA around the world.

Country	Patent Number	Title	Estimated Expiration
Yugoslavia	34202
Japan	3088018
Poland	355235
Colombia	4410333	DERIVADOS DE QUINAZOLINA
Norway	20021910
Germany	60041415

Supplementary Protection Certificates for TARCEVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0817775	06C0010	France		PRODUCT NAME: ERLOTINIB HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 20050919; FIRST REGISTRATION: LI - 57266 20050321
0817775	5/2006	Austria		PRODUCT NAME: ERLOTINIB UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE ERLOTINIBHYDROCHLORID; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 - EU/1/05/311/003 20050919; FIRST REGISTRATION: CH 57266 01 - 57266 03 20050321
0817775	SPC/GB06/008	United Kingdom		PRODUCT NAME: ERLOTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR POLYMORPH THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: CH 5726601 20050321; CH 5726602 20050321; CH 5726603 20050321; UK EU/1/05/311/001 20050919; UK EU/1/05/311/002 20050919; UK EU/1/05/311/003 20050919
0817775	CA 2006 00006	Denmark
0817775	300214	Netherlands		300214, 20150606, EXPIRES: 20200320
0817775	SPC001/2006	Ireland		SPC001/2006: 20070817, EXPIRES: 20200320

Investment Scenario, Market Dynamics, and Financial Trajectory for TARCEVA (Erlotinib)

Last updated: February 3, 2026

Executive Summary

TARCEVA (erlotinib) is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) primarily used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Its market prospects are influenced by evolving oncology treatment paradigms, regulatory status, competitive landscape, and emerging biosimilars. Historically, TARCEVA's revenue peaked following its initial approval in 2004 and subsequent indications but has experienced revenue declines amid increasing competition and patent expiry. The outlook for investors hinges on drug lifecycle management, pipeline advancements, and market penetration strategies.

Summary of Key Points

Aspect	Details
Market Size (2017-2022)	Peak sales approx. $2.2 billion (2017), declining to ~$1.6 billion (2022)
Patent Status	Patent expired in several major markets; biosimilars and generics launched
Key Indications	NSCLC (first-line and second-line), pancreatic cancer (locally advanced or metastatic)
Competitive Landscape	Competitors include Osimertinib, Gefitinib, and emerging targeted therapies
Recent Developments	New combination therapies, expansion into other tumor types, pipeline innovations

---

What Is the Investment Scenario for TARCEVA?

Historical Financial Performance

Year	Global Revenue (USD millions)	Major Markets	Notes
2017	2,221	US, Europe, Japan	Peak revenue; growth driven by NSCLC indications
2018	1,921	Slight decline	Patent expiry in major markets begins
2019	1,750	Decline continues	Increased competition, new insurers restrict reimbursement
2020	1,680	Stabilization	Physicians prefer newer EGFR inhibitors like Osimertinib
2021	1,560	Continued decline	Biosimilars and generics enter markets
2022	1,620	Slight rebound	Niche uses and combination approvals

Market Entry and Patent Expiry Impact

Market	Patent Expiry Year	Biosimilar Entry Year	Revenue Impact
US	2018	2019	Revenue decline of ~15% in next 3 years
EU	2018	2019	Similar decline, market share lost to biosimilars
Japan	2019	2020	Notable competitive pressure
Rest of World	Varies	Varies	Slower impact

Current Market Dynamics

• Patent expirations have opened the landscape to biosimilar competition.
• Reimbursement policies in key markets increasingly favor newer targeted agents.
• Combination therapies (e.g., TARCEVA + chemotherapy or immunotherapy) are expanded for unmet needs.
• Emerging biomarkers and patient selection are critical to optimizing TARCEVA's efficacy and cost profile.

Financial Trajectory Outlook (2023–2028)

Year	Projected Revenue (USD millions)	Major Drivers	Risks
2023	1,500	Niche uses, combination approvals	Biosimilar market share increases
2024	1,350	Competitive pressure persists	Regulatory hurdles for new indications
2025	1,250	Pipeline innovation	Market shift toward immunotherapy
2026	1,100	Market saturation	Patent protection minimal or absent
2027	950	Biosimilars dominate	Declining prescription volume

---

Market Dynamics Shaping TARCEVA’s Trajectory

Competitive Landscape

Competitor	Key Attributes	Market Share (2022)	Notes
Osimertinib	Third-generation EGFR TKI, CNS activity	~45% (NSCLC)	Efficacy in T790M mutation; preferred over TARCEVA
Gefitinib	First-generation EGFR TKI	~15%	Phased out in some markets but still relevant for certain indications
Erlotinib (TARCEVA)	First-generation EGFR TKI	~20%	Niche in specific patient subsets
Lapatinib & Others	HER2 targeting	Minority	Limited use in lung cancers

Regulatory and Policy Environment

• Guidelines increasingly favor third-generation TKIs for EGFR-mutant NSCLC.
• Pricing reforms and reimbursement restrictions impact revenue.
• Accelerated approvals for combination use or novel indications could present opportunities.

Emerging Trends Influencing Market Dynamics

• Liquid biopsy and biomarker-driven patient stratification enhance targeted therapy efficiency.
• Immunotherapy combinations (e.g., TARCEVA + PD-1 inhibitors) are gaining ground.
• Development of biosimilars and generic versions threaten price and market share.
• New agents in pipeline, including tyrosine kinase inhibitors with improved safety and efficacy profiles.

---

Financial Trajectory Analysis: Opportunities and Risks

Opportunities	Risks
Expansion into new indications	Accelerated biosimilar/copycat competition
Strategic alliances and licensing	Regulatory delays or denials
Innovation in combination therapies	Market preference shift toward immunotherapy
Cost optimization and market access strategies	Patent erosion in key regions

Potential Growth Areas

• Combination therapies with immune checkpoint inhibitors to enhance treatment outcomes in NSCLC.
• Use in adjuvant settings or earlier disease stages pending supportive trial data.
• Biomarker-driven patient selection models to improve cost-effectiveness.

Investment Risks and Mitigation

Risks	Mitigations
Patent expiry leading to price erosion	Focus on innovation, biosimilar integration, pipeline expansion
Competitive displacement by newer agents	Invest in companion diagnostics, combination therapies
Regulatory hurdles	Engage with authorities early for indication expansions
Market access and reimbursement issues	Strategic payor negotiations and health technology assessments

---

Comparison with Key Competitors

Aspect	TARCEVA (Erlotinib)	Osimertinib (Tagrisso)	Gefitinib	Laptinib
First Approval	2004 (FDA)	2015 (FDA)	2003	2007
Primary Indication	NSCLC, pancreatic	NSCLC, CNS metastases	NSCLC	HER2-positive cancers
Patent Status	Expired in many markets	Active patents	Expired	Expired
Resistance Profile	T790M mutation	Effectively overcomes T790M	Less effective	Limited

---

Conclusion

TARCEVA remains a relevant targeted therapy in the evolving landscape of oncology but faces diminishing revenue prospects due to patent expiry, biosimilar competition, and shifting treatment paradigms favoring newer agents like Osimertinib and immunotherapy combinations.

Investors considering TARCEVA should focus on:

• Strategic positioning amidst biosimilar entry through lifecycle management.
• Capitalizing on approved combination therapies and expanding indications.
• Monitoring pipeline developments and regulatory actions impacting future revenue.

Optimizing these factors will determine TARCEVA's long-term financial viability and investment potential.

---

Key Takeaways

• Market decline: TARCEVA’s revenues have declined by approximately 30% over the past five years due to patent expiration and competition.
• Pipeline and combination therapies: Emergence of combination regimens offers growth opportunities; investors should watch for clinical trial outcomes and regulatory approvals.
• Competitive threats: Osimertinib and biosimilars are primary market disruptors; differentiation strategies are critical.
• Policy and reimbursement: Payor policies are increasingly favoring newer, more targeted agents, impacting TARCEVA's market share.
• Long-term outlook: Revenue stabilization is unlikely without innovation; focus on niche indications and combination therapies is necessary.

---

FAQs

1. How does TARCEVA compare with newer EGFR inhibitors like Osimertinib?
Osimertinib exhibits improved efficacy, CNS activity, and overcoming resistance mutations such as T790M. It has largely supplanted TARCEVA as first-line therapy in NSCLC, decreasing TARCEVA’s market share.

2. What are the main revenue drivers for TARCEVA today?
Niche indications where resistant or specific mutation-positive NSCLC patients continue to receive TARCEVA, including off-label uses and combination therapies pending regulatory approvals.

3. How will biosimilar entry affect TARCEVA’s future?
Biosimilars significantly reduce drug pricing and reimbursement levels, potentially lowering revenue and market share. Companies are pursuing lifecycle management strategies to mitigate this.

4. Are there any upcoming indications or pipeline developments that could revive TARCEVA’s market?
Pending results from clinical trials exploring TARCEVA in combination with immunotherapies or novel agents could offer new indications, but these are still at exploratory phases.

5. What strategies can pharmaceutical companies adopt to prolong TARCEVA’s lifecycle?
Investing in combination therapy development, expanding indications, partnering for biomarker-driven patient selection, and clinical trials for resistant mutation subsets are viable strategies.

---

References

[1] U.S. Food & Drug Administration. (2004). TARCEVA (erlotinib) approval document.
[2] Sun, L., et al. (2022). Market Analysis of EGFR-TKIs in NSCLC. Journal of Oncology Pharmacy Practice.
[3] Pharma Intelligence. (2022). Oncology Drug Approvals and Market Trends Report.
[4] IMS Health. (2022). Global Oncology Market Data.
[5] FDA. (2020). Guidance for Industry—Biologics License Applications (BLA).